<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Postsynaptic density-95 inhibitors reduce ischemic brain damage without inhibiting excitatory neurotransmission, circumventing the negative consequences of glutamatergic inhibition </plain></SENT>
<SENT sid="1" pm="."><plain>However, their efficacy in permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and in providing permanent neuroprotection and neurobehavioral improvement in a practical therapeutic window is unproven </plain></SENT>
<SENT sid="2" pm="."><plain>These were tested here under conditions that included <z:hpo ids='HP_0001945'>fever</z:hpo>, which is a common occurrence in clinical <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Six studies were performed in unfasted Sprague-Dawley rats </plain></SENT>
<SENT sid="4" pm="."><plain>Two involved permanent pial vessel occlusion in male and female rats </plain></SENT>
<SENT sid="5" pm="."><plain>Two involved permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, which induced severe <z:hpo ids='HP_0001945'>hyperthermia</z:hpo>, and 2 involved transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Animals were treated with a single intravenous injection of postsynaptic density-95 inhibitors (Tat-NR2B9c([SDV]) or Tat-NR2B9c([TDV])) 1 hour or 3 hours after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volumes and neurobehavior were assessed in a blinded manner at 24 hours (pial vessel occlusion and permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>) or at 62 days (transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>) </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Postsynaptic density-95 inhibitors dramatically reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size in male and female animals exposed to pial vessel occlusion (&gt;50%), in hyperthermic animals with <z:hpo ids='HP_0001945'>fever</z:hpo> exceeding 39 degrees C exposed to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (approximately 50%), and at 62 days poststroke in animals exposed to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (approximately 80%) </plain></SENT>
<SENT sid="9" pm="."><plain>Effectiveness of postsynaptic density-95 inhibitors was achieved without the drugs affecting body temperature </plain></SENT>
<SENT sid="10" pm="."><plain>In transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, a single dose of postsynaptic density-95 inhibitor given 3 hours after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> permanently maintained reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improved neurobehavior </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Postsynaptic density-95 inhibitors administrated 3 hours after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and improved long-term neurobehavioral functions in a wide therapeutic window </plain></SENT>
<SENT sid="12" pm="."><plain>This raises the possibility that they may have future clinical usefulness </plain></SENT>
</text></document>